Wang Ya-Ru, Ma Yan-Ping
Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Jun;31(3):769-776. doi: 10.19746/j.cnki.issn.1009-2137.2023.03.022.
To analyze the expression level of nicotinamide phosphoribosyltransferase (NAMPT ) in bone marrow of multiple myeloma (MM) patients and its correlation with clinicopathological features, clinical efficacy and prognosis.
RT-qPCR and Western blot were used to detect the expression of NAMPT mRNA and protein in bone marrow mononuclear cells from 85 newly diagnosed MM patients (including 17 relapsed MM patients) and 15 healthy donors, and explore the correlation of the expression of gene with clinicopathological features and efficacy. Kaplan-Meier method was used to analyze the effects of on progression-free survival (PFS) and overall survival (OS), and univariate and multivariate survival analysis were performed.
The median expression level of mRNA in bone marrow of newly diagnosed and relapsed MM patients was significantly higher than that of healthy donors ( <0.001). The expression of mRNA in relapsed MM patients was significantly higher than that in newly diagnosed MM patients ( <0.001), which was consistent with the expression of NAMPT protein. ISS staging, lactate dehydrogenase and C-reactive protein levels, p53 deletion and the proportion of myeloma cells were increased in high expression group compared with low expression group ( <0.001). Compared with complete remission group, mRNA expression was significantly up-regulated in partial remission group, progression group and relapsed group ( <0.001). The median OS and PFS of patients in high expression group was 27.3 and 14.9 months, respectively, which was significantly shorter than 39.1 and 27 months in low expression group ( =0.048, <0.001). Both univariate and multivariate analysis showed that expression was correlated with PFS and OS.
The expression level of in newly diagnosed and relapsed MM patients is significantly higher than that in normal controls, and its up-regulation is related to the adverse clinical characteristics, efficacy and prognosis of MM patients. is an independent prognostic risk factor of MM.
分析烟酰胺磷酸核糖转移酶（NAMPT）在多发性骨髓瘤（MM）患者骨髓中的表达水平及其与临床病理特征、临床疗效和预后的相关性。
采用逆转录定量聚合酶链反应（RT-qPCR）和蛋白质免疫印迹法（Western blot）检测85例新诊断MM患者（包括17例复发MM患者）及15例健康供者骨髓单个核细胞中NAMPT mRNA和蛋白的表达，探讨该基因表达与临床病理特征及疗效的相关性。采用Kaplan-Meier法分析其对无进展生存期（PFS）和总生存期（OS）的影响，并进行单因素和多因素生存分析。
新诊断及复发MM患者骨髓中NAMPT mRNA的中位表达水平显著高于健康供者（P<0.001）。复发MM患者中NAMPT mRNA的表达显著高于新诊断MM患者（P<0.001），这与NAMPT蛋白的表达情况一致。与低表达组相比，高表达组的国际分期系统（ISS）分期、乳酸脱氢酶和C反应蛋白水平、p53缺失及骨髓瘤细胞比例均升高（P<0.001）。与完全缓解组相比，部分缓解组、疾病进展组和复发组中NAMPT mRNA表达均显著上调（P<0.001）。高表达组患者的中位OS和PFS分别为27.3个月和14.9个月，显著短于低表达组的39.1个月和27个月（P=0.048，P<0.001）。单因素和多因素分析均显示，NAMPT表达与PFS和OS相关。
新诊断及复发MM患者中NAMPT的表达水平显著高于正常对照，其上调与MM患者不良的临床特征、疗效及预后相关。NAMPT是MM的独立预后危险因素。
